<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126685</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000435933</org_study_id>
    <secondary_id>ERLANGEN-DERMA-ER-DC-07</secondary_id>
    <secondary_id>EU-20513</secondary_id>
    <secondary_id>ARGOS-ERLANGEN-DERMA-DC-07</secondary_id>
    <nct_id>NCT00126685</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Stage IV Melanoma</brief_title>
  <official_title>Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With Unselected Autologous Amplified Tumor-RNA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body&#xD;
      build an effective immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of vaccine therapy and to see how&#xD;
      well it works in treating patients with stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of vaccine therapy comprising autologous dendritic&#xD;
           cells (DC) transfected with autologous polymerase chain reaction-amplified tumor RNA in&#xD;
           patients with stage IV cutaneous melanoma.&#xD;
&#xD;
        -  Determine whether tumor RNA- or tumor antigen-specific T-cell responses are induced in&#xD;
           patients treated with this vaccine.&#xD;
&#xD;
        -  Determine whether there are major differences in the immunogenicity of DC transfected at&#xD;
           immature stage or at mature stage in patients treated with this vaccine.&#xD;
&#xD;
        -  Determine objective tumor response in patients treated with this vaccine.&#xD;
&#xD;
        -  Determine time to disease progression and progression-free interval in patients treated&#xD;
           with this vaccine.&#xD;
&#xD;
        -  Determine overall survival of patients treated with this vaccine.&#xD;
&#xD;
      OUTLINE: This is an open-label, nonrandomized study. Patients are sequentially assigned to&#xD;
      receive dendritic cells (DC) transfected at either immature or mature stage.&#xD;
&#xD;
      Approximately 2-3 weeks before leukapheresis, patients undergo surgical excision or biopsy of&#xD;
      the tumor to obtain tumor tissue for RNA isolation. RNA is amplified from the tumor sample by&#xD;
      polymerase chain reaction (PCR). Patients then undergo leukapheresis to harvest peripheral&#xD;
      blood mononuclear cells for the production of DC on day -14 . DC at immature or mature stage&#xD;
      are transfected with autologous PCR-amplified tumor RNA to produce the vaccine. Patients&#xD;
      receive vaccine intradermally (ID) on days 1, 15, 29, 43, 57, and between days 71-74 in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients undergo evaluation between&#xD;
      days 71-74. Patients with responding or stable disease or minor disease progression receive&#xD;
      booster vaccine ID on days 99, 127, between days 162-164, on day 205, between days 253-255,&#xD;
      351-354, 442-444, 533-535, 624-626, and 715-718 in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients also undergo additional leukapheresis between days 71-74,&#xD;
      351-354, and 715-718. Patients with responding or stable disease may continue to undergo&#xD;
      leukapheresis and receive booster vaccine ID every 12-24 weeks off study.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 10 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8-30 patients will be accrued for this study within 6-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2005</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective tumor response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to disease progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free interval</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous tumor cell vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cutaneous melanoma*&#xD;
&#xD;
               -  Stage IV disease (i.e., distant metastasis)&#xD;
&#xD;
               -  Not curable by surgical resection&#xD;
&#xD;
          -  NOTE: *Metastatic melanoma with an unknown primary tumor allowed provided ocular&#xD;
             melanoma can be definitely excluded and origin from the skin is likely&#xD;
&#xD;
          -  Unidimensionally or bidimensionally measurable disease by physical examination and/or&#xD;
             noninvasive radiological procedures&#xD;
&#xD;
               -  At least 1 measurable metastasis that has not been previously excised or biopsied&#xD;
&#xD;
          -  Failed ≥ 1 standard chemotherapy or chemoimmunotherapy regimen (e.g., dacarbazine or&#xD;
             cisplatin monotherapy)&#xD;
&#xD;
          -  At least 1 metastatic lesion surgically accessible* for excision or biopsy to obtain&#xD;
             tumor material for RNA isolation** NOTE: *Surgically accessible metastatic lesion not&#xD;
             required provided properly processed tumor material or isolated tumor RNA is available&#xD;
             from a metastasis excised or biopsied within the past 6 months&#xD;
&#xD;
        NOTE: **Major surgery not allowed for the acquisition of metastatic material solely for RNA&#xD;
        isolation&#xD;
&#xD;
          -  No active CNS metastases by CT scan or MRI&#xD;
&#xD;
               -  Previously treated CNS metastases (e.g., by excision of a single metastasis,&#xD;
                  gamma knife radiosurgery, or stereotactic radiotherapy) allowed provided there is&#xD;
                  no evidence of active CNS metastasis by CT scan or MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC &gt; 2,500/mm^3&#xD;
&#xD;
          -  Neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Lymphocyte count &gt; 700/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  No bleeding disorders&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine &lt; 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant heart disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No respiratory disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV-1 or -2 negative&#xD;
&#xD;
          -  Human T-cell lymphotropic virus type I negative&#xD;
&#xD;
          -  No known hypersensitivity to dimethylsulfoxide&#xD;
&#xD;
          -  No immunodeficiency disease&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No active autoimmune disease (except vitiligo), including any of the following:&#xD;
&#xD;
               -  Lupus erythematosus&#xD;
&#xD;
               -  Scleroderma&#xD;
&#xD;
               -  Rheumatoid arthritis (i.e., rheumatoid factor-positive arthritis with current or&#xD;
                  recent flare)&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  Autoimmune thyroiditis or uveitis&#xD;
&#xD;
               -  Autoimmune hemolytic anemia&#xD;
&#xD;
               -  Immune thrombocytopenic purpura&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile female patients must use effective contraception during and for ≥ 4 weeks&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  Willing to undergo excision or biopsy of metastasis&#xD;
&#xD;
          -  Willing to be hospitalized for ≥ 24 hours after each vaccination&#xD;
&#xD;
          -  Medical condition stable&#xD;
&#xD;
          -  No contraindication to leukapheresis&#xD;
&#xD;
          -  No organic brain syndrome&#xD;
&#xD;
          -  No significant psychiatric abnormality that would preclude study participation&#xD;
&#xD;
          -  No other active malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other major serious illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior systemic immunotherapy&#xD;
&#xD;
          -  No systemic immunotherapy during and for 2 weeks after completion of study treatment&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior systemic chemotherapy&#xD;
&#xD;
          -  No systemic chemotherapy during and for 2 weeks after completion of study treatment&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No systemic corticosteroids, including steroid-containing inhalers or chronic use of&#xD;
             topical steroids over large areas of the body (if systemic effects are likely or&#xD;
             obvious) during and for 2 weeks after completion of study treatment&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the spleen&#xD;
&#xD;
          -  Concurrent palliative radiotherapy to selected metastases for pain or local&#xD;
             complications (e.g., compression) allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  No prior splenectomy&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  Concurrent palliative surgery to selected metastases for pain or local complications&#xD;
             (e.g., compression) allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Concurrent palliative hyperthermic therapy to selected metastases for pain or local&#xD;
             complications (e.g., compression) allowed&#xD;
&#xD;
          -  No concurrent participation in any other clinical trial&#xD;
&#xD;
          -  No other systemic immunosuppressive agents (e.g., azathioprine or cyclosporine) during&#xD;
             and for 2 weeks after completion of study treatment&#xD;
&#xD;
          -  No other investigational drugs or paramedical substances during and for 2 weeks after&#xD;
             completion of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Schuler</last_name>
    <role>Study Chair</role>
    <affiliation>Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2005</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

